Objective: To evaluate effectiveness and safety of adalimumab in CD patients of the Madrid area and identify predictors of response.

Methods: Multicenter retrospective survey of all CD patients treated with adalimumab in 9 hospitals of the Madrid area (Spain). Univariate and multivariate analysis of predictors of response was performed.

Results: 174 patients included (50% males) with a median follow-up of 40 weeks. 30% had active perianal fistulizing disease at the beginning of the therapy with adalimumab. 59% had been previously treated with infliximab, being the lost of response (42.2%) the most frequent cause of withdrawal of the drug. 33% of patients needed dose escalation from every-other week to every week. The median time for this dose escalation was 33 weeks (range 2-120). The percentages of complete response at 4 weeks, 6 months and end of follow-up were 63, 70 and 63% in luminal disease and 49, 50 and 41% in perianal disease respectively. The prevalence of adverse events was 18% (most frequent was: 5 abscesses) causing the withdrawal of the drug in 21% of them.

Conclusions: Adalimumab is effective and safe for the management of CD, even in refractory cases to infliximab.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gastrohep.2011.04.001DOI Listing

Publication Analysis

Top Keywords

adalimumab effective
8
madrid area
8
withdrawal drug
8
dose escalation
8
adalimumab
5
effective long-term
4
long-term real
4
real life
4
life clinical
4
clinical practice
4

Similar Publications

Introduction: This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA).

Methods: This retrospective, non-interventional study used the OPAL dataset, derived from electronic medical records. Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023.

View Article and Find Full Text PDF

Background: The armamentarium of medical therapies to treat inflammatory bowel disease (IBD) continues to grow, which has expanded treatment options, particularly after first biologic failure. Currently, there are limited studies investigating the predictive value of first biologic primary non-response (PNR) on subsequent biologic success. Our objective was to determine if PNR to the first biologic for IBD is predictive of response to subsequent biologic therapy.

View Article and Find Full Text PDF

Background: Axial Spondyloarthritis (axSpA) is a chronic inflammatory rheumatic condition affecting the axial skeleton, leading to pain, stiffness, and fatigue. While biologic therapies have improved clinical management, many patients experience partial or no responses, resulting in delays in disease control. Additionally, the risk of adverse events and increased costs remains a concern.

View Article and Find Full Text PDF

Objectives: To evaluate the clinical features of pediatric non-infectious uveitis (NIU) patients treated with adalimumab (ADA) and the efficacy of ADA in patients unresponsive to conventional immunosuppressive therapy.

Materials And Methods: The records of 91 NIU patients aged ≤16 years who received ADA therapy were evaluated retrospectively. The patients' demographic and clinical characteristics and treatment approaches were recorded.

View Article and Find Full Text PDF

Successful Treatment of Annular Atrophic Lichen Planus With Adalimumab.

Clin Case Rep

January 2025

Department of Geriatric Medicine, Nimes Hospital University Medical Center University of Balamand, Faculty of Medicine and Medical Sciences Balamand Lebanon.

Adalimumab may be an effective treatment for resistant annular atrophic lichen planus, especially in patients with prior treatment failures and contraindications to other systemic therapies. This case underscores the need for exploring systemic options in challenging cases of this rare lichen planus variant.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!